{"description":"Documents matching 'product problem break fluid blood'","count":511,"total_pages":26,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bterm%5D=product+problem+break+fluid+blood&format=json&page=2","results":[{"title":"Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products","type":"Proposed Rule","abstract":"The Food and Drug Administration (FDA, the Agency, or we) is proposing a tobacco product standard that would regulate nicotine yield by establishing a maximum nicotine level in cigarettes and certain other combusted tobacco products. FDA is proposing this action to reduce the addictiveness of these products, thus giving people who are addicted and wish to quit the ability to do so more easily. The proposed product standard is anticipated to benefit the population as a whole. For example, it would help to prevent people who experiment with cigarettes and cigars from developing addiction and using combusted tobacco products regularly.","document_number":"2025-00397","html_url":"https://www.federalregister.gov/documents/2025/01/16/2025-00397/tobacco-product-standard-for-nicotine-yield-of-cigarettes-and-certain-other-combusted-tobacco","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-01-16/pdf/2025-00397.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-00397.pdf?1736948724","publication_date":"2025-01-16","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"non-cigarette tobacco <span class=\"match\">products</span>, such as electronic nicotine delivery systems (ENDS) (which include e-cigarettes) and smokeless tobacco <span class=\"match\">products</span>, in the scope of this proposed <span class=\"match\">product</span> standard. As discussed throughout this document, nicotine is the primary addictive constituent in \n \n tobacco <span class=\"match\">products</span>, and it is the nicotine in such <span class=\"match\">products</span> that both creates and sustains addiction and ultimately leads to the significant adverse health effects caused by these <span class=\"match\">products</span>. While these effects raise concerns in the context of any tobacco <span class=\"match\">product</span>—none of which"},{"title":"N-(1,3-Dimethylbutyl)-N′-phenyl-p-phenylenediamine (6PPD) and its Transformation Product, 6PPD-quinone; Regulatory Investigation Under the Toxic Substances Control Act (TSCA)","type":"Proposed Rule","abstract":"In granting a petition filed under the Toxic Substances Control Act (TSCA) by Earthjustice on behalf of the Yurok Tribe, the Port Gamble S'Klallam Tribe, and the Puyallup Tribe of Indians, the Environmental Protection Agency (EPA or Agency) committed to pursuing an action to solicit and collect information from the public on the potential risks associated with N-(1,3-Dimethylbutyl)-N'-phenyl-p- phenylenediamine (6PPD) (CASRN 793-24-8, DTXSID 9025114) and its transformation product, 6PPD-quinone (CASRN 2754428-18-5, DTXSID 301034849). With this document, EPA is soliciting that information, along with information about potential alternatives and regulatory options to help inform the Agency's consideration of potential future regulatory actions under TSCA.","document_number":"2024-26894","html_url":"https://www.federalregister.gov/documents/2024/11/19/2024-26894/n-13-dimethylbutyl-n-phenyl-p-phenylenediamine-6ppd-and-its-transformation-product-6ppd-quinone","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-11-19/pdf/2024-26894.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-26894.pdf?1731937532","publication_date":"2024-11-19","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"and other rubber <span class=\"match\">products</span> to prevent degradation. As a solid, 6PPD is dark brown with violet flakes and is generally sold as pellets, pastilles, or in liquid form (Refs. 4 and 5). 6PPD can diffuse easily to the surface of a rubber <span class=\"match\">product</span> and quickly react with ozone (O\n 3 \n ) to protect the rubber polymers from oxidation (Ref. 5). This chain of events occurs quickly enough to effectively protect the rubber but slowly enough to last for the lifetime of the <span class=\"match\">product</span>, which has made 6PPD a useful antidegradant for use in rubber <span class=\"match\">products</span> (Ref. 6).\n \n 2"},{"title":"Procedures for Transportation Workplace Drug and Alcohol Testing Programs: Addition of Oral Fluid Specimen Testing for Drugs","type":"Rule","abstract":"This final rule amends the U.S. Department of Transportation's regulated industry drug testing program to include oral fluid testing. This additional methodology for drug testing will give employers a choice that will help combat employee cheating on urine drug tests and provide a less intrusive means of achieving the safety goals of the program. In order for an employer to implement oral fluid testing under the Department's regulation, the U.S. Department of Health and Human Services will need to certify at least two laboratories for oral fluid testing, which has not yet been done. The final rule includes other provisions to update the Department's regulation and to harmonize, as needed, with the Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid established by the U.S. Department of Health and Human Services. In addition, this rule amends the FAA, FMCSA, FRA and FTA regulations to ensure consistency within the Department of Transportation and by removing or adjusting references to the word \"urine\" and/or add references to oral fluid, as well as removing or amending some definitions for conformity and to make other miscellaneous technical changes or corrections.","document_number":"2023-08041","html_url":"https://www.federalregister.gov/documents/2023/05/02/2023-08041/procedures-for-transportation-workplace-drug-and-alcohol-testing-programs-addition-of-oral-fluid","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-05-02/pdf/2023-08041.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-08041.pdf?1682945116","publication_date":"2023-05-02","agencies":[{"raw_name":"DEPARTMENT OF TRANSPORTATION","name":"Transportation Department","id":492,"url":"https://www.federalregister.gov/agencies/transportation-department","json_url":"https://www.federalregister.gov/api/v1/agencies/492","parent_id":null,"slug":"transportation-department"},{"raw_name":"Federal Aviation Administration","name":"Federal Aviation Administration","id":159,"url":"https://www.federalregister.gov/agencies/federal-aviation-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/159","parent_id":492,"slug":"federal-aviation-administration"},{"raw_name":"Office of the Secretary"},{"raw_name":"Federal Railroad Administration","name":"Federal Railroad Administration","id":185,"url":"https://www.federalregister.gov/agencies/federal-railroad-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/185","parent_id":492,"slug":"federal-railroad-administration"},{"raw_name":"Federal Motor Carrier Safety Administration","name":"Federal Motor Carrier Safety Administration","id":181,"url":"https://www.federalregister.gov/agencies/federal-motor-carrier-safety-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/181","parent_id":492,"slug":"federal-motor-carrier-safety-administration"},{"raw_name":"Federal Transit Administration","name":"Federal Transit Administration","id":193,"url":"https://www.federalregister.gov/agencies/federal-transit-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/193","parent_id":492,"slug":"federal-transit-administration"}],"excerpts":"positive vs. negative oral <span class=\"match\">fluid</span> result reported by the laboratory for THC). We have added definitions for “oral <span class=\"match\">fluid</span> specimen” and “urine specimen.” We have added a sentence to the definition of “oral <span class=\"match\">fluid</span> specimen” to explicitly state that an oral <span class=\"match\">fluid</span> collection is a direct observation collection. “Specimen” is the generic term for any <span class=\"match\">fluid</span>, breath or material collected from someone for a \n \n drug or alcohol test. We have added “Undiluted (neat) oral <span class=\"match\">fluid</span>”, using the same language HHS uses in Section 1.5 of its Oral <span class=\"match\">Fluid</span> Mandatory Guidelines"},{"title":"Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings","type":"Proposed Rule","abstract":"OSHA is proposing to issue a new standard, titled Heat Injury and Illness Prevention in Outdoor and Indoor Work Settings. The standard would apply to all employers conducting outdoor and indoor work in all general industry, construction, maritime, and agriculture sectors where OSHA has jurisdiction, with some exceptions. It would be a programmatic standard that would require employers to create a plan to evaluate and control heat hazards in their workplace. It would more clearly set forth employer obligations and the measures necessary to effectively protect employees from hazardous heat. OSHA requests comments on all aspects of the proposed rule.","document_number":"2024-14824","html_url":"https://www.federalregister.gov/documents/2024/08/30/2024-14824/heat-injury-and-illness-prevention-in-outdoor-and-indoor-work-settings","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-08-30/pdf/2024-14824.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-14824.pdf?1724935516","publication_date":"2024-08-30","agencies":[{"raw_name":"DEPARTMENT OF LABOR","name":"Labor Department","id":271,"url":"https://www.federalregister.gov/agencies/labor-department","json_url":"https://www.federalregister.gov/api/v1/agencies/271","parent_id":null,"slug":"labor-department"},{"raw_name":"Occupational Safety and Health Administration","name":"Occupational Safety and Health Administration","id":386,"url":"https://www.federalregister.gov/agencies/occupational-safety-and-health-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/386","parent_id":271,"slug":"occupational-safety-and-health-administration"}],"excerpts":"conducted light exercise in a heat chamber and were provided one of four <span class=\"match\">fluid</span> replacement quantities: no <span class=\"match\">fluid</span>, one-third <span class=\"match\">fluid</span> replacement, two-thirds <span class=\"match\">fluid</span> replacement, or complete <span class=\"match\">fluid</span> replacement (based on previously determined sweat rates). Each participant completed two 20-minute exercise periods, separated by a 10-minute <span class=\"match\">break</span> for a simulated self-contained breathing apparatus (SCBA) change, and then followed by a 20-minute rest <span class=\"match\">break</span>. Cool water was provided during each <span class=\"match\">break</span>. Exercise continued until participants reached an endpoint, defined"},{"title":"Mandatory Toy Safety Standards: Requirements for Neck Floats","type":"Proposed Rule","abstract":"The Consumer Product Safety Improvement Act of 2008 (CPSIA) mandates that ASTM F963 shall be a mandatory toy safety standard. This toy safety standard sets forth only minimal labeling requirements for aquatic toys such as neck floats. The U.S. Consumer Product Safety Commission (CPSC or Commission) proposes to establish new performance and revised labeling requirements to address potentially deadly hazards associated with neck floats. The Commission also proposes to amend CPSC's list of notice of requirements (NORs) to include neck floats.","document_number":"2024-25446","html_url":"https://www.federalregister.gov/documents/2024/11/20/2024-25446/mandatory-toy-safety-standards-requirements-for-neck-floats","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-11-20/pdf/2024-25446.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-25446.pdf?1732023915","publication_date":"2024-11-20","agencies":[{"raw_name":"CONSUMER PRODUCT SAFETY COMMISSION","name":"Consumer Product Safety Commission","id":84,"url":"https://www.federalregister.gov/agencies/consumer-product-safety-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/84","parent_id":null,"slug":"consumer-product-safety-commission"}],"excerpts":"retailers advertise the <span class=\"match\">products</span> for children 0 to 6 months for small sizes, 6 to 18 months for medium sizes, and 2 to 5 years for large sizes. The <span class=\"match\">products</span> generally are marketed for use in bathtubs and pools with direct parental supervision. Retail prices for neck float <span class=\"match\">products</span> intended for children typically range from $10 to $60 depending on material type and art design, with inherently buoyant <span class=\"match\">products</span> being more expensive than inflatable <span class=\"match\">products</span>. \n Section 3.1.92 of ASTM F963-23 defines a “toy” as “any object designed, manufactured, or marketed"},{"title":"Licensing Requirements for Microreactors and Other Reactors With Comparable Risk Profiles","type":"Proposed Rule","abstract":"The U.S. Nuclear Regulatory Commission (NRC) is proposing to amend its regulations to establish a risk-informed and performance- based regulatory framework for rapid licensing of new microreactors and other reactors with comparable risk profiles and for high-volume deployment of these reactors. The proposed rule would provide a flexible set of licensing pathways, reduce regulatory burden, and ensure that safety and security requirements remain commensurate with the potential hazards posed by these facilities.","document_number":"2026-08550","html_url":"https://www.federalregister.gov/documents/2026/05/01/2026-08550/licensing-requirements-for-microreactors-and-other-reactors-with-comparable-risk-profiles","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-01/pdf/2026-08550.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08550.pdf?1777553125","publication_date":"2026-05-01","agencies":[{"raw_name":"NUCLEAR REGULATORY COMMISSION","name":"Nuclear Regulatory Commission","id":383,"url":"https://www.federalregister.gov/agencies/nuclear-regulatory-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/383","parent_id":null,"slug":"nuclear-regulatory-commission"}],"excerpts":"a split specimen for all drug tests using oral <span class=\"match\">fluid</span> or urine for all test conditions in proposed § 26.907(b), “Test conditions,” and (j), “<span class=\"match\">Blood</span> testing.” Neither current subpart K nor current subparts B or E of part 26 require a split specimen. However, many of the LWR fleet uses split specimens for drug testing, and commercially available drug screening <span class=\"match\">products</span> use a split specimen technique. Since publication of the 2008 part 26 final rule, the HHS has issued guidelines for urine and oral <span class=\"match\">fluid</span> specimen testing that require split specimen collections"},{"title":"n-Methylpyrrolidone (NMP); Regulation Under the Toxic Substances Control Act (TSCA)","type":"Proposed Rule","abstract":"The Environmental Protection Agency (EPA or the \"Agency\") is proposing to address the unreasonable risk of injury to human health presented by n-methylpyrrolidone (NMP) under its conditions of use as documented in EPA's risk evaluation and risk determination for NMP pursuant to the Toxic Substances Control Act (TSCA). NMP is a widely used solvent in a variety of industrial, commercial, and consumer applications including the manufacture and production of electronics such as semiconductors, polymers, petrochemical products, paints and coatings, and paint and coating removers. EPA determined that NMP presents an unreasonable risk of injury to health due to the significant adverse health effects associated with exposure to NMP, including developmental post-implantation fetal loss from short-term exposure and reduced fertility and fecundity from long-term exposure. Additional adverse effects associated with exposure to NMP include liver toxicity, kidney toxicity, immunotoxicity, neurotoxicity, skin irritation, and sensitization. To address the identified unreasonable risk, EPA is proposing to: prohibit the manufacture (including import), processing, and distribution in commerce and use of NMP in several occupational conditions of use; require worker protections through an NMP workplace chemical protection program (WCPP) or prescriptive controls (including concentration limits) for most of the occupational conditions of use; require concentration limits on a consumer product; regulate certain consumer products to prevent commercial use; and establish recordkeeping, labeling, and downstream notification requirements.","document_number":"2024-12643","html_url":"https://www.federalregister.gov/documents/2024/06/14/2024-12643/n-methylpyrrolidone-nmp-regulation-under-the-toxic-substances-control-act-tsca","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-06-14/pdf/2024-12643.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-12643.pdf?1718282716","publication_date":"2024-06-14","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"consumer use of NMP-containing <span class=\"match\">products</span> in adhesive and sealant <span class=\"match\">products</span>.\n \n \n vi. \n Consumer use in automotive care <span class=\"match\">products</span>. \n This condition of use refers to consumer use of NMP-containing <span class=\"match\">products</span> in automotive care <span class=\"match\">products</span>. This description includes automotive interior cleaning <span class=\"match\">products</span>.\n \n \n vii. \n Consumer use in cleaning and furniture care <span class=\"match\">products</span>, including wood cleaners and gasket removers. \n This condition of use refers to consumer use of NMP-containing <span class=\"match\">products</span> in cleaning and furniture care <span class=\"match\">products</span>, including wood cleaners and gasket"},{"title":"Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program","type":"Rule","abstract":"This major final rule addresses: changes to the physician fee schedule (PFS); other changes to Medicare Part B payment policies to ensure that payment systems are updated to reflect changes in medical practice, relative value of services, and changes in the statute; codification of establishment of new policies for: the Medicare Prescription Drug Inflation Rebate Program under the Inflation Reduction Act of 2022; the Ambulatory Specialty Model; updates to the Medicare Diabetes Prevention Program expanded model; updates to drugs and biological products paid under Part B; Medicare Shared Savings Program requirements; updates to the Quality Payment Program; updates to policies for Rural Health Clinics and Federally Qualified Health Centers; update to the Ambulance Fee Schedule regulations; codification of the Inflation Reduction Act and Consolidated Appropriations Act, 2023 provisions; updates to the Medicare Promoting Interoperability Program.","document_number":"2025-19787","html_url":"https://www.federalregister.gov/documents/2025/11/05/2025-19787/medicare-and-medicaid-programs-cy-2026-payment-policies-under-the-physician-fee-schedule-and-other","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-11-05/pdf/2025-19787.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-19787.pdf?1761945018","publication_date":"2025-11-05","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"available skin substitute <span class=\"match\">products</span>, the sales and distribution structure for these <span class=\"match\">products</span>, and the rapidity of <span class=\"match\">products</span> changing manufacturer ownership. These industry changes are causing a significant increase in spending under Medicare Part B for skin substitute <span class=\"match\">products</span> in the non-facility setting. According to Medicare claims data, Part B spending for these <span class=\"match\">products</span> rose from approximately $250 million in 2019 to over $10 billion in 2024, a nearly 40-fold increase, while the number of patients receiving these <span class=\"match\">products</span> only doubled. Increases"},{"title":"Food Labeling: Nutrient Content Claims; Definition of Term “Healthy”","type":"Rule","abstract":"The Food and Drug Administration (FDA or we) is issuing this final rule updating the definition for the implied nutrient content claim \"healthy\" to be consistent with current nutrition science and Federal dietary guidance, especially the Dietary Guidelines for Americans (Dietary Guidelines), regarding how consumers can maintain healthy dietary practices. This final rule revises the requirements for when the term \"healthy\" can be used as an implied nutrient content claim in the labeling of human food products to help consumers identify foods that are particularly useful as the foundation of a nutritious diet that is consistent with dietary recommendations.","document_number":"2024-29957","html_url":"https://www.federalregister.gov/documents/2024/12/27/2024-29957/food-labeling-nutrient-content-claims-definition-of-term-healthy","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-12-27/pdf/2024-29957.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-29957.pdf?1734624913","publication_date":"2024-12-27","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"foods such as yogurts and bakery <span class=\"match\">products</span>, the mere presence of pastes and purees in those <span class=\"match\">products</span> does not enable such <span class=\"match\">products</span> to qualify for use of the claim. Food <span class=\"match\">products</span>, such as bakery <span class=\"match\">products</span> containing fruit pastes and purees, would continue to be evaluated based on the overall criteria set forth for their food category. Likewise, packaged <span class=\"match\">products</span> of fruit pastes and purees would be evaluated on the criteria set forth for fruit <span class=\"match\">products</span>, regardless of any potential use as ingredients in other food <span class=\"match\">products</span>.\n \n 5. FGE for Grains and Whole"},{"title":"Clean Water Act Effluent Limitations Guidelines and Standards for the Meat and Poultry Products Point Source Category","type":"Proposed Rule","abstract":"The Environmental Protection Agency (EPA or the Agency) is proposing a regulation to revise the technology-based effluent limitations guidelines and standards (ELGs) for the meat and poultry products (MPP) point source category. The proposed rule would improve water quality and protect human health and the environment by reducing the discharge of nutrients and other pollutants to the nation's surface waters. EPA is proposing several regulatory options, including the preferred option discussed in this notice. The preferred option is estimated to cost $232 million annually and reduce pollutant discharges by approximately 100 million pounds per year.","document_number":"2023-28498","html_url":"https://www.federalregister.gov/documents/2024/01/23/2023-28498/clean-water-act-effluent-limitations-guidelines-and-standards-for-the-meat-and-poultry-products","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-01-23/pdf/2023-28498.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-28498.pdf?1705931114","publication_date":"2024-01-23","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"the CWA.\n \n \n Finished <span class=\"match\">Product</span>. \n The final manufactured <span class=\"match\">product</span> produced on site, including <span class=\"match\">products</span> intended for consumption with no additional processing as well as <span class=\"match\">products</span> intended for further processing, when applicable.\n \n \n First Processing. \n Operations which receive live meat animals or poultry and produce a raw, dressed meat or poultry <span class=\"match\">product</span>, either whole or in parts.\n \n \n FTE. \n Full Time Equivalent Employee\n \n \n Further Processing. \n Operations which utilize whole carcasses or cut-up meat or poultry <span class=\"match\">products</span> for the production of fresh"},{"title":"Child Nutrition Programs: Meal Patterns Consistent With the 2020-2025 Dietary Guidelines for Americans","type":"Rule","abstract":"This rulemaking finalizes long-term school nutrition requirements based on the goals of the Dietary Guidelines for Americans, 2020-2025, robust stakeholder input, and lessons learned from prior rulemakings. Notably, this rulemaking gradually phases in added sugars limits for the school lunch and breakfast programs and in the Child and Adult Care Food Program, updates total sugars limits for breakfast cereals and yogurt to added sugars limits. As a reflection of feedback from stakeholders, this final rule implements a single sodium reduction in the school lunch and breakfast programs and commits to studying the potential associations between sodium reduction and student participation in the school lunch and breakfast programs. This rulemaking addresses a variety of other school meal requirements, including establishing long-term milk and whole grain requirements. Finally, this rule includes provisions that strengthen Buy American requirements. While this rulemaking takes effect school year 2024-2025, the Department is gradually phasing in required changes over time. Program operators are not required to make any changes to their menus as a result of this rulemaking until school year 2025-2026 at the earliest.","document_number":"2024-08098","html_url":"https://www.federalregister.gov/documents/2024/04/25/2024-08098/child-nutrition-programs-meal-patterns-consistent-with-the-2020-2025-dietary-guidelines-for","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-04-25/pdf/2024-08098.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-08098.pdf?1713962726","publication_date":"2024-04-25","agencies":[{"raw_name":"DEPARTMENT OF AGRICULTURE","name":"Agriculture Department","id":12,"url":"https://www.federalregister.gov/agencies/agriculture-department","json_url":"https://www.federalregister.gov/api/v1/agencies/12","parent_id":null,"slug":"agriculture-department"},{"raw_name":"Food and Nutrition Service","name":"Food and Nutrition Service","id":200,"url":"https://www.federalregister.gov/agencies/food-and-nutrition-service","json_url":"https://www.federalregister.gov/api/v1/agencies/200","parent_id":12,"slug":"food-and-nutrition-service"}],"excerpts":"to the cost of <span class=\"match\">product</span> reformulation. An advocacy group also raised concerns about <span class=\"match\">product</span> reformulation, noting that each time a food producer needs to change the specifications of a <span class=\"match\">product</span>, it can take up to three years and cost as much as $750,000 per item. This respondent was concerned that some manufacturers may choose to stop making school-specific items instead of reformulating their <span class=\"match\">products</span>. \n Proposed Approach: <span class=\"match\">Product</span>-Based Limits \n Over 86,000 respondents, including 96 unique comments, supported the proposed <span class=\"match\">product</span>-based limits in"},{"title":"Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments","type":"Rule","abstract":"This final rule addresses: changes to the physician fee schedule (PFS); other changes to Medicare Part B payment policies to ensure that payment systems are updated to reflect changes in medical practice, relative value of services, and changes in the statute; codification of establishment of new policies for, the Medicare Prescription Drug Inflation Rebate Program under the Inflation Reduction Act of 2022; updates to the Medicare Diabetes Prevention Program expanded model; payment for dental services inextricably linked to specific covered medical services; updates to drugs and biological products paid under Part B including immunosuppressive drugs and clotting factors; Medicare Shared Savings Program requirements; updates to the Quality Payment Program; Medicare coverage of opioid use disorder services furnished by opioid treatment programs; updates to policies for Rural Health Clinics and Federally Qualified Health Centers; electronic prescribing for controlled substances for a covered Part D drug under a prescription drug plan or a Medicare Advantage Prescription Drug (MA-PD) plan under the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act); update to the Ambulance Fee Schedule regulations; codification of the Inflation Reduction Act and Consolidated Appropriations Act, 2023 provisions; updates to Clinical Laboratory Fee Schedule regulations; updates to the diabetes payment structure and PHE flexibilities; expansion of colorectal cancer screening and Hepatitis B vaccine coverage and payment; establishing payment for drugs covered as additional preventive services; Medicare Parts A and B Overpayment Provisions of the Affordable Care Act and Medicare Parts C and D Overpayment Provisions of the Affordable Care Act.","document_number":"2024-25382","html_url":"https://www.federalregister.gov/documents/2024/12/09/2024-25382/medicare-and-medicaid-programs-cy-2025-payment-policies-under-the-physician-fee-schedule-and-other","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-12-09/pdf/2024-25382.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-25382.pdf?1730492138","publication_date":"2024-12-09","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"three types of <span class=\"match\">products</span> that may be considered refundable single-dose container or single-use package drugs under paragraph (1). These are:\n \n (1) <span class=\"match\">Product</span> furnished from a single-dose container or single-use package based on FDA-approved labeling or <span class=\"match\">product</span> information. \n (2) <span class=\"match\">Product</span> furnished from an ampule for which <span class=\"match\">product</span> labeling does not have a discard statement or language indicating the package type term, like “single-dose container,” “single-use package,” “multiple-dose container,” or “single-patient-use container”. \n (3) <span class=\"match\">Product</span> furnished from"},{"title":"Hazardous Drugs: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 and Final Reevaluation Determinations for Liraglutide and Pertuzumab","type":"Notice","abstract":"The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), in the Department of Health and Human Services (HHS), announces the publication of the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024, as well as final reevaluation determinations removing the drugs liraglutide and pertuzumab from the NIOSH List of Hazardous Drugs in Healthcare Settings.","document_number":"2024-30456","html_url":"https://www.federalregister.gov/documents/2024/12/20/2024-30456/hazardous-drugs-niosh-list-of-hazardous-drugs-in-healthcare-settings-2024-and-final-reevaluation","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-12-20/pdf/2024-30456.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-30456.pdf?1734615932","publication_date":"2024-12-20","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Disease Control and Prevention","name":"Centers for Disease Control and Prevention","id":44,"url":"https://www.federalregister.gov/agencies/centers-for-disease-control-and-prevention","json_url":"https://www.federalregister.gov/api/v1/agencies/44","parent_id":221,"slug":"centers-for-disease-control-and-prevention"}],"excerpts":"had listed names that were not actual <span class=\"match\">products</span> or were different <span class=\"match\">products</span> than originally intended.\n \n \n NIOSH response: \n NIOSH appreciates the commenters who brought up this issue and regrets the confusion that this caused. NIOSH has revised the 2024 \n List \n to include the FDA assigned prefixes (\n i.e., \n ziv-, ado-, and fam-) in the appropriate generic drugs names (ziv-aflibercept, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan) to correct the issue and refer to the appropriate pharmaceutical <span class=\"match\">products</span>.\n \n H. Suggested Copyedits \n \n Public"},{"title":"Taking and Importing Marine Mammals; Taking Marine Mammals Incidental to Geophysical Surveys in the Gulf of America","type":"Proposed Rule","abstract":"NMFS has received a request for the reimplementation of incidental take regulations (ITR) governing the incidental taking of marine mammals during geophysical survey activity conducted in the Gulf of America (GOA). Pursuant to the Marine Mammal Protection Act (MMPA), NMFS is requesting comments on its proposed rule and will consider public comments relevant to this proposed rule prior to issuing any final rule.","document_number":"2026-03691","html_url":"https://www.federalregister.gov/documents/2026/02/24/2026-03691/taking-and-importing-marine-mammals-taking-marine-mammals-incidental-to-geophysical-surveys-in-the","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-02-24/pdf/2026-03691.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-03691.pdf?1771622109","publication_date":"2026-02-24","agencies":[{"raw_name":"DEPARTMENT OF COMMERCE","name":"Commerce Department","id":54,"url":"https://www.federalregister.gov/agencies/commerce-department","json_url":"https://www.federalregister.gov/api/v1/agencies/54","parent_id":null,"slug":"commerce-department"},{"raw_name":"National Oceanic and Atmospheric Administration","name":"National Oceanic and Atmospheric Administration","id":361,"url":"https://www.federalregister.gov/agencies/national-oceanic-and-atmospheric-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/361","parent_id":54,"slug":"national-oceanic-and-atmospheric-administration"}],"excerpts":"following restrictions: (1) a maximum of 2 consecutive hours on watch followed by a <span class=\"match\">break</span> of at least 1 hour between watches for visual PSOs; (2) a maximum of 4 consecutive hours on watch followed by a <span class=\"match\">break</span> of at least 2 consecutive hours between watches for PAM operators; and (3) a maximum of 12 hours observation per 24-hour period. NMFS may grant an exception for the requirement that visual PSOs be limited to a maximum of 2 consecutive hours on watch followed by a <span class=\"match\">break</span> of at least 1 hour between watches if requested on the basis of practicability"},{"title":"Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments","type":"Proposed Rule","abstract":"This major proposed rule addresses: changes to the physician fee schedule (PFS); other changes to Medicare Part B payment policies to ensure that payment systems are updated to reflect changes in medical practice, relative value of services, and changes in the statute; codification of, and proposing policies for, the Medicare Prescription Drug Inflation Rebate Program under the Inflation Reduction Act of 2022; updates to the Medicare Diabetes Prevention Program expanded model; payment for dental services inextricably linked to specific covered medical services; updates to drugs and biological products paid under Part B including immunosuppressive drugs and clotting factors; Medicare Shared Savings Program requirements; updates to the Quality Payment Program; Medicare coverage of opioid use disorder services furnished by opioid treatment programs; updates to policies for Rural Health Clinics and Federally Qualified Health Centers; electronic prescribing for controlled substances for a covered Part D drug under a prescription drug plan or a Medicare Advantage Prescription Drug (MA-PD) plan under the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act); update to the Ambulance Fee Schedule regulations; codification of the Inflation Reduction Act and Consolidated Appropriations Act, 2023 provisions; updates to Clinical Laboratory Fee Schedule regulations; updates to the diabetes payment structure and PHE flexibilities; expansion of colorectal cancer screening and Hepatitis B vaccine coverage and payment; establishing payment for drugs covered as additional preventive services; Medicare Parts A and B Overpayment Provisions of the Affordable Care Act.","document_number":"2024-14828","html_url":"https://www.federalregister.gov/documents/2024/07/31/2024-14828/medicare-and-medicaid-programs-cy-2025-payment-policies-under-the-physician-fee-schedule-and-other","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-07-31/pdf/2024-14828.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-14828.pdf?1720642528","publication_date":"2024-07-31","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"three types of <span class=\"match\">products</span> that may be considered refundable single-dose container or single-use package drugs under paragraph (1). These are:\n \n (1) <span class=\"match\">Product</span> furnished from a single-dose container or single-use package based on FDA-approved labeling or <span class=\"match\">product</span> information. \n (2) <span class=\"match\">Product</span> furnished from an ampule for which <span class=\"match\">product</span> labeling does not have discard statement or language indicating the package type term, like “single-dose container,” “single-use package,” “multiple-dose container,” or “single-patient-use container”. \n (3) <span class=\"match\">Product</span> furnished from"},{"title":"Advanced Impaired Driving Prevention Technology","type":"Proposed Rule","abstract":"This document initiates rulemaking that would gather the information necessary to develop performance requirements and require that new passenger motor vehicles be equipped with advanced drunk and impaired driving prevention technology through a new Federal Motor Vehicle Safety Standard (FMVSS). In this document, NHTSA presents its various activities related to preventing drunk and impaired driving and discusses the current state of advanced impaired driving technology. NHTSA also asks many questions to gather the information necessary to develop a notice of proposed rulemaking on advanced drunk and impaired driving technology.","document_number":"2023-27665","html_url":"https://www.federalregister.gov/documents/2024/01/05/2023-27665/advanced-impaired-driving-prevention-technology","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-01-05/pdf/2023-27665.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-27665.pdf?1704375914","publication_date":"2024-01-05","agencies":[{"raw_name":"DEPARTMENT OF TRANSPORTATION","name":"Transportation Department","id":492,"url":"https://www.federalregister.gov/agencies/transportation-department","json_url":"https://www.federalregister.gov/api/v1/agencies/492","parent_id":null,"slug":"transportation-department"},{"raw_name":"National Highway Traffic Safety Administration","name":"National Highway Traffic Safety Administration","id":345,"url":"https://www.federalregister.gov/agencies/national-highway-traffic-safety-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/345","parent_id":492,"slug":"national-highway-traffic-safety-administration"}],"excerpts":"driver's breath. BAC is usually measured via a <span class=\"match\">blood</span> test. Technology is under development that would allow for measurement in new ways. For example, one technology uses touch- or tissue-based detection of light absorption at pre-selected wavelengths from a beam of light reflected from within the skin tissue after an optical module is touched. In other words, BAC is calculated either by a <span class=\"match\">blood</span> test or, in the future, after someone touches a sensor and that sensor calculates the BAC level in the person's <span class=\"match\">blood</span>. NHTSA acknowledges that people may be affected"},{"title":"Risk-Informed, Technology-Inclusive Regulatory Framework for Advanced Reactors","type":"Rule","abstract":"The U.S. Nuclear Regulatory Commission (NRC) is amending its regulations by adding a risk-informed, performance-based, and technology-inclusive regulatory framework for commercial nuclear plants in response to the Nuclear Energy Innovation and Modernization Act (NEIMA). The current application and licensing requirements were primarily developed to address license requests concerning light water- cooled reactors and operational requirements for those types of reactors. This final rule responds to NEIMA by creating an alternative, technology-inclusive regulatory framework to accommodate licensing of future commercial nuclear plants, including advanced reactor designs that may not employ light-water technology.","document_number":"2026-06048","html_url":"https://www.federalregister.gov/documents/2026/03/30/2026-06048/risk-informed-technology-inclusive-regulatory-framework-for-advanced-reactors","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-03-30/pdf/2026-06048.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-06048.pdf?1774615514","publication_date":"2026-03-30","agencies":[{"raw_name":"NUCLEAR REGULATORY COMMISSION","name":"Nuclear Regulatory Commission","id":383,"url":"https://www.federalregister.gov/agencies/nuclear-regulatory-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/383","parent_id":null,"slug":"nuclear-regulatory-commission"}],"excerpts":"an HHS-certified laboratory, certified for that biological specimen, except for invalid specimens that cannot be tested.\n \n \n (g) \n Oral <span class=\"match\">fluid</span> testing. \n (1) If the licensee or other entity elects to use oral <span class=\"match\">fluid</span> for drug or alcohol testing, the collection, packaging, temporary storage, and shipment of an oral <span class=\"match\">fluid</span> specimen to an HHS-certified laboratory for drug testing, or the collection of an oral <span class=\"match\">fluid</span> specimen for alcohol testing must be performed in accordance with licensee- or other entity-established procedures based either on the requirements"},{"title":"Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Rating; Hospital Price Transparency; and Notice of Closure of a Teaching Hospital and Opportunity To Apply for Available Slots","type":"Rule","abstract":"This final rule with comment period revises the Medicare Hospital Outpatient Prospective Payment System (OPPS) and the Medicare Ambulatory Surgical Center (ASC) payment system for calendar year 2026 based on our continuing experience with these systems. We also describe the changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment systems. In addition, this final rule with comment period announces the closure of a teaching hospital and the opportunity to apply for available slots, and updates and refines the requirements for the Hospital Outpatient Quality Reporting Program, Rural Emergency Hospital Quality Reporting Program, Ambulatory Surgical Center Quality Reporting Program, Overall Hospital Quality Star Rating, and hospitals to make public their standard charge information and enforcement of hospital price transparency, as well as summarizes comments received in response to a request for information on measure concepts regarding Well-Being and Nutrition for consideration in future years for the OQR, REHQR, and ASCQR programs.","document_number":"2025-20907","html_url":"https://www.federalregister.gov/documents/2025/11/25/2025-20907/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-11-25/pdf/2025-20907.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-20907.pdf?1763759710","publication_date":"2025-11-25","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"},{"raw_name":"Office of the Secretary"}],"excerpts":" (1) <span class=\"match\">Blood</span> and <span class=\"match\">Blood</span> <span class=\"match\">Products</span> \n Since the implementation of the OPPS in August 2000, we have made separate payments for <span class=\"match\">blood</span> and <span class=\"match\">blood</span> <span class=\"match\">products</span> through APCs rather than packaging payment for them into payments for the procedures with which they are administered. Hospital payments for the costs of <span class=\"match\">blood</span> and <span class=\"match\">blood</span> <span class=\"match\">products</span>, as well as for the costs of collecting, processing, and storing <span class=\"match\">blood</span> and <span class=\"match\">blood</span> <span class=\"match\">products</span>, are made through the OPPS payments for specific <span class=\"match\">blood</span> <span class=\"match\">product</span> APCs. \n We proposed to continue to establish payment rates for <span class=\"match\">blood</span> and blood"},{"title":"Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs, Including the Hospital Inpatient Quality Reporting Program; Health and Safety Standards for Obstetrical Services in Hospitals and Critical Access Hospitals; Prior Authorization; Requests for Information; Medicaid and CHIP Continuous Eligibility; Medicaid Clinic Services Four Walls Exceptions; Individuals Currently or Formerly in Custody of Penal Authorities; Revision to Medicare Special Enrollment Period for Formerly Incarcerated Individuals; and All-Inclusive Rate Add-On Payment for High-Cost Drugs Provided by Indian Health Service and Tribal Facilities","type":"Rule","abstract":"This final rule with comment period revises the Medicare Hospital Outpatient Prospective Payment System (OPPS) and the Medicare Ambulatory Surgical Center (ASC) payment system for calendar year 2025 based on our continuing experience with these systems. We describe the changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment system. Also, this final rule updates the requirements for the Hospital Outpatient Quality Reporting Program, Rural Emergency Hospital Quality Reporting Program, Ambulatory Surgical Center Quality Reporting Program, and Hospital Inpatient Quality Reporting Program. We also summarize information received in response to a Request for Information on potential modifications to the Safety of Care measure group in the Overall Hospital Quality Star Rating methodology. In this final rule, we are also finalizing our proposal to narrow the description of \"custody\" in the Medicare payment exclusion rule and to revise the special enrollment period criteria for formerly incarcerated individuals. We are also finalizing our Medicaid and Children's Health Insurance Program (CHIP) continuous eligibility provisions. We are also finalizing the proposal to reduce the review timeframe for standard prior authorization requests for certain covered outpatient department services paid under the OPPS from 10-business days to 7-calendar days. Further, this rule finalizes updates to the Conditions of Participation (CoPs) for hospitals and critical access hospitals (CAHs) in an effort to advance the health and safety of pregnant, birthing, and postpartum women. This rule also finalizes our proposed policy to separately pay Indian Health Service (IHS) and Tribal hospitals for high-cost drugs furnished in hospital outpatient departments through an add-on payment in addition to the all-inclusive rate (AIR) under the authorities used to calculate the AIR starting January 1, 2025. Finally, we are finalizing exceptions to the Medicaid clinic services four walls requirement for IHS and Tribal clinics, and, at state option, for behavioral health clinics and clinics located in rural areas.","document_number":"2024-25521","html_url":"https://www.federalregister.gov/documents/2024/11/27/2024-25521/medicare-and-medicaid-programs-hospital-outpatient-prospective-payment-and-ambulatory-surgical","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-11-27/pdf/2024-25521.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-25521.pdf?1730492130","publication_date":"2024-11-27","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"APC Criteria-Based Costs \n (1) <span class=\"match\">Blood</span> and <span class=\"match\">Blood</span> <span class=\"match\">Products</span> \n (a) Methodology \n Since the implementation of the OPPS in August 2000, we have made separate payments for <span class=\"match\">blood</span> and <span class=\"match\">blood</span> <span class=\"match\">products</span> through APCs rather than packaging payment for them into payments for the procedures with which they are administered. Hospital payments for the costs of <span class=\"match\">blood</span> and <span class=\"match\">blood</span> <span class=\"match\">products</span>, as well as for the costs of collecting, processing, and storing <span class=\"match\">blood</span> and <span class=\"match\">blood</span> <span class=\"match\">products</span>, are made through the OPPS payments for specific <span class=\"match\">blood</span> <span class=\"match\">product</span> APCs. \n \n In the CY 2025 OPPS/ASC"},{"title":"Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals (IPPS) and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year (FY) 2026 Rates; Changes to the FY 2025 IPPS Rates Due to Court Decision; Requirements for Quality Programs; and Other Policy Changes; Health Data, Technology, and Interoperability: Electronic Prescribing, Real-Time Prescription Benefit and Electronic Prior Authorization","type":"Rule","abstract":"This final rule revises the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals; makes changes relating to Medicare graduate medical education (GME) for teaching hospitals; updates the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs); updates and makes changes to requirements for certain quality programs; and makes other policy- related changes. We are also finalizing the provisions of the interim final action with comment period regarding the changes to the FY 2025 IPPS rates due to the court decision in Bridgeport Hosp. v. Becerra. Lastly, it finalizes certain updates to the ONC Health Information Technology (IT) Certification Program.","document_number":"2025-14681","html_url":"https://www.federalregister.gov/documents/2025/08/04/2025-14681/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-ipps-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-08-04/pdf/2025-14681.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-14681.pdf?1753992911","publication_date":"2025-08-04","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"},{"raw_name":"Office of the Secretary"}],"excerpts":"the possibility of immunotherapy <span class=\"match\">products</span> administered over multiple encounters. Given that we cannot predict all possible scenarios where the <span class=\"match\">product</span> is not purchased in the usual manner, use of a condition code that reflects a broad array of circumstances will facilitate more accurate payment and ratesetting. We further note that the “usual manner” in which a <span class=\"match\">product</span> is purchased may differ for <span class=\"match\">products</span> administered in one dose versus split doses. \n \n Comment: \n Commenters noted that some immunotherapy <span class=\"match\">products</span> may be administered over multiple"}]}